For a patient with gastric cancer and active Crohn’s disease, what treatment should be initiated, especially regarding the use of immunotherapy?

Management of Active Crohn's Disease in a Patient with Gastric Cancer on Immunotherapy

For a patient with gastric cancer requiring immunotherapy who has active Crohn's disease, initiate vedolizumab as the preferred biologic therapy for Crohn's disease management, as it provides gut-selective immunosuppression with minimal systemic immune interference that could compromise anti-tumor responses.

Rationale and Treatment Algorithm

Primary Crohn's Disease Management

The severity of active Crohn's disease dictates the initial approach:

For moderate to severe active Crohn's disease:

• Vedolizumab is the optimal first-line biologic 1. This gut-selective α4β7 integrin antagonist provides strong recommendation with moderate-quality evidence for inducing complete remission in patients who fail conventional therapy 1.
• Evaluate symptomatic response between 10-14 weeks to determine need for therapy modification 1.
• If vedolizumab achieves symptomatic response, continue maintenance therapy (strong recommendation, moderate-quality evidence) 1.

Why vedolizumab over anti-TNF therapy in this context:

• Anti-TNF agents (infliximab, adalimumab) carry theoretical risk of interfering with anti-tumor immune responses when combined with cancer immunotherapy
• Vedolizumab's gut-selective mechanism minimizes systemic immunosuppression, preserving anti-tumor immunity
• The Canadian guidelines provide strong recommendations for vedolizumab in patients failing conventional therapy 1

Gastric Cancer Immunotherapy Considerations

Continue cancer immunotherapy based on tumor characteristics:

• For HER2-negative gastric adenocarcinoma with PD-L1 CPS ≥5: nivolumab plus chemotherapy 2
• For HER2-positive gastric/GEJ adenocarcinoma: trastuzumab plus pembrolizumab with chemotherapy 2

Critical Safety Monitoring

Watch for immune checkpoint inhibitor (ICI) colitis:

• ICIs can cause or exacerbate inflammatory bowel disease in 25.7% of patients 3
• Active baseline IBD status significantly increases risk of GI adverse events (20.0% vs 14.5%, P=0.025) 3
• ICI use is associated with decreased survival when GI adverse events occur (HR: 2.0, P<0.0001) 3

If ICI-induced colitis develops despite vedolizumab:

• First-line: High-dose corticosteroids (methylprednisolone 1-2 mg/kg/day)
• Refractory cases: Infliximab (5 mg/kg) is effective for ICI colitis 4
• If infliximab fails: Switch to vedolizumab (or vice versa if vedolizumab was used first) 4
• Do not wait for standard washout periods—treat within weeks if prior biologic fails 4

Alternative Approaches if Vedolizumab Unavailable or Contraindicated

Second-line option: Ustekinumab (IL-12/23 inhibitor)

• Strong recommendation for moderate to severe Crohn's disease failing conventional therapy 1
• Evaluate response between 6-10 weeks 1
• Less data on interaction with cancer immunotherapy but theoretically safer than anti-TNF

Avoid in this specific scenario:

• Anti-TNF monotherapy (infliximab, adalimumab): Risk of blunting anti-tumor immune responses
• JAK inhibitors (tofacitinib): Substantial risk of interfering with anti-tumor responses 4
• Abatacept (CTLA-4-Ig): Direct mechanism-based interference with checkpoint inhibitor efficacy 4

Bridging Therapy for Immediate Symptom Control

If hospitalization required for severe disease:

• Intravenous methylprednisolone 40-60 mg/day 1
• Evaluate response within 1 week 1
• Transition to vedolizumab for long-term management
• Do not use oral corticosteroids for maintenance (strong recommendation against) 1

Key Clinical Pitfalls

1. Do not delay biologic therapy: Waiting for conventional immunosuppressants (thiopurines, methotrexate) is inappropriate given their slow onset (12-16 weeks) and the urgency of managing both conditions 1

2. Pre-existing IBD is not a contraindication to immunotherapy: While IBD patients were excluded from ICI trials, active disease should not prevent cancer treatment if ICIs are the only effective option 4

3. Monitor closely for ICI colitis: This can occur even with prophylactic IBD treatment and requires aggressive management to prevent treatment discontinuation and mortality 4, 3

4. Avoid thiopurine monotherapy: Conditional recommendation against using thiopurines alone to induce remission in any severity of Crohn's disease 1

Multidisciplinary Coordination Required

Close collaboration between oncology and gastroenterology is essential, with:

• Shared decision-making about biologic selection
• Coordinated monitoring schedules (vedolizumab response at 10-14 weeks; cancer response per oncology protocols)
• Rapid escalation protocols if either condition worsens
• Clear communication about any new GI symptoms that could represent ICI colitis versus Crohn's flare